Navigation Links
Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
Date:10/3/2011

BURLINGTON, Mass., Oct. 3, 2011 /PRNewswire/-- Coronado Biosciences, Inc. today announced the appointment of Noah D. Beerman as Executive Vice President and Chief Operating Officer effective September 26, 2011.

Dr. Bobby W. Sandage, Jr., Coronado's President and CEO, said, "Noah brings with him a breadth of experience from an extensive career holding senior management positions in the industry. With his leadership and expertise in business operations, corporate development, and financing emerging biopharmaceutical companies, he will be a key asset as we execute the Company's business plan, work to maximize shareholder value, and increase our visibility. We are pleased to welcome him to the Coronado team at such an exciting time for the Company."

Mr. Beerman has over 25 years experience in the biopharmaceutical industry. Before joining Coronado as a consultant in May 2011, Mr. Beerman served as President and Chief Executive Officer and a Director of Galena Biopharma, formerly RXi Pharmaceuticals Corporation, from November 2009 until April 2011 where he successfully completed two equity financings, significantly improved Wall Street visibility for the company, and developed and implemented a focused therapeutic and clinical strategy.  Prior to joining RXi, he spent more than 10 years at Indevus Pharmaceuticals, Inc. serving most recently as Executive Vice President, Chief Business Officer from September 2004 until the sale of the company to Endo Pharmaceuticals, Inc. in 2009. Mr. Beerman holds an M.B.A. from Northeastern University's High Technology Program graduating Beta Gamma Sigma, and a B.S. in molecular genetics from the University of Rochester graduating Phi Beta Kappa, Magna Cum Laude. 

About Coronado BiosciencesCoronado Biosciences is engaged in the development of novel immunotherapy biologic agents.  The Company's two principal pharmaceutical product candidates in clinical development are: CNDO-201, a bio
'/>"/>

SOURCE Coronado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
2. Coronado Biosciences Closes $25.8M in Series C Financing
3. Coronado Biosciences Files to Become a Public Reporting Company
4. Coronado Biosciences to Present at the Rodman & Renshaw Annual Global Investment Conference
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
11. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... SINGAPORE , Sept. 15, 2014  Catalist-listed QT ... "the Group"), a developer and manufacturer of minimally invasive ... pleased to announce that the Group has enrolled the ... Germany . Multiple patients have already been ... , at Auckland City Hospital, in Auckland, ...
(Date:9/15/2014)... Sept. 15, 2014 PDL BioPharma, Inc. (PDL) (NASDAQ: ... paid the September 12, 2014, regular quarterly dividend payment of ... PDL as of September 5, 2014, the record date. ... manages a portfolio of patents and royalty assets, consisting ... and license agreements with various biotechnology and pharmaceutical companies. ...
(Date:9/15/2014)... , Sept. 15, 2014 Research and ... "Closed Drug Transfer Systems to 2020" report to ... deemed hazardous to humans has been receiving increasing amounts ... these substances become more clearly understood. For caregivers and ... forefront of attempts to mitigate exposure to cytotoxic drugs ...
Breaking Medicine Technology:First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5PDL BioPharma Completes Regular Quarterly Dividend Payment 2Closed Drug Transfer Systems to 2020 2Closed Drug Transfer Systems to 2020 3
... Doubled Time to Progression and Overall Response Rate as ... in Patients with 2nd or 3rd Line Metastatic Colon ... KERX ) today announced data on the ... cancer, in combination with capecitabine as a treatment for ...
... increase the risk of breast cancer recurrence , ... found that taking tamoxifen with certain antidepressants more than ... taking both medications. The antidepressants inhibit an enzyme, CYP2D6, ... ) , , The study ...
Cached Medicine Technology:Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 2Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 3Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 4Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 5Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 6New Research Shows Antidepressants May Thwart Breast Cancer Treatment 2New Research Shows Antidepressants May Thwart Breast Cancer Treatment 3
(Date:9/15/2014)... one out of every 40 individuals in the United States ... atrophy (SMA), a neurodegenerative disease that causes muscles to weaken ... made a recent breakthrough with the development of a new ... the disease. In April, a patent was filed for the ... is using to fight SMA is to ,repress the repressor," ...
(Date:9/15/2014)... September 15, 2014 In order to ... medicine often act conjointly to quantify, define and model ... become an integral part of medical care. , The ... the studies conducted by the non-profit Institute of BioAcoustic ... demonstrated that math can be much more than a ...
(Date:9/15/2014)... Dennis Thompson ... News) -- The severe respiratory virus believed to have ... states has now spread to the Northeast, health officials ... confirmed on Friday more than a dozen cases of ... for children with asthma. And on Saturday, the ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 As ... end of its first full year, there are ... maturing; especially in the evolution of its marketing ... approach being taken by Denver's Kindman, one of ... and distributors. , Kindman has pioneered the first-ever ...
(Date:9/15/2014)... September 15, 2014 As Risperdal lawsuits ... Bernstein Liebhard LLP notes that a new study has ... curbing aggression in children with ADHD when it is ... in behavioral management techniques. According to a report from ... and aggression problems, half of whom took Concerta, a ...
Breaking Medicine News(10 mins):Health News:Researcher develops and proves effectiveness of new drug for spinal muscular atrophy 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 3Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 3Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 2Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 2Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 4
... 2008) University of Minnesota researchers have created a beating ... called whole organ decellularization, scientists from the University of Minnesota ... dead rat and pig hearts and reseeding them with a ... in the January 13 issue of Nature Medicine., The ...
... injected into ,skeleton, of animal organ was beating in ... -- An organ-building biotechnology that could create transplantable hearts ... important laboratory tests, researchers report. , The technique, called ... heart tissue, according to a report in the Jan. ...
... here today," says James, a ClearChoices speaker. "I was,addicted ... I was at dinner each,night... they thought everything was ... and prevent them from going through what I went ... Chrysler LLC and,Barrett- Jackson will allow notMYkid to educate ...
... 500 Executive Driving Global Breast Cancer Leader,s Promise ... End Breast Cancer Forever, ATLANTA, Jan. 12 Hala ... the global leader in the fight to end breast,cancer forever, ... annual Trumpet Awards event in Atlanta with a ,High Heels ...
... LAUDERDALE, Fla., Jan. 11 eDiets.com,Inc. (Nasdaq: DIET ... Hamilton. Mr. Hamilton, who joined the Company in November,1999, ... privately held,company. Mr. Hamilton will remain available to assist ... firm to find a replacement and has,appointed Carla Cox, ...
... CHAPEL HILL, N.C., Jan. 11 Today,s top-level,pharmaceutical ... the,team that will carry out the plan as ... study by pharmaceutical research firm, Best,Practices, LLC., ... looking to invest people and money earlier in ...
Cached Medicine News:Health News:U of M researchers create beating heart in laboratory 2Health News:Biotechnology Builds a New Heart 2Health News:Biotechnology Builds a New Heart 3Health News:First in Nation: notMYkid Educational Center Is Now a Reality Thanks to a Partnership Between Chrysler, Barrett-Jackson and notMYkid 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 3Health News:eDiets.com, Inc. Announces Resignation of Robert Hamilton, Chief Financial Officer 2Health News:eDiets.com, Inc. Announces Resignation of Robert Hamilton, Chief Financial Officer 3Health News:Global Pharmaceutical Launches: Best Practices for Winning Product Launch Successes 2
... LactoSorb copolymer is an absorbable co-polymer ... acid and 18% glycolic acid. Unlike ... as 100% poly-L-lactic acid (PLLA) or ... is substantially amorphous (without crystallinity), meaning ...
... Tissue Anchor 2 mm is a resorbable repair ... using sutures. The resorbable repair device is implanted ... is used to reattach damaged soft tissue. The ... derived from glycolide and lactide colored with D&C ...
... of anchor is generally used when ... This 2.9mm anchor is packaged sterile ... or 2-0) and needles. Although pre-drilling ... the Mini Harpoon®, 1.6mm & 1.8mm ...
The MINI-TAG™ instrument systems are indicated for ulnar collateral ligament repair, scapholunate dissolution, flexor avulsions, and carpometa-carpal arthroplasty....
Medicine Products: